The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
Purpose: Triple-negative breast cancer (TNBC) is the most dangerous subtype of breast cancer with high rates of metastasis and recurrence. The efficacy of capecitabine in chemotherapy for TNBC is still controversial. This study evaluated the efficacy and safety of capecitabine combining with standar...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/153e29c373eb4cc1b7b86dbb9ba1318c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:153e29c373eb4cc1b7b86dbb9ba1318c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:153e29c373eb4cc1b7b86dbb9ba1318c2021-11-15T04:40:25ZThe Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis1663-981210.3389/fphar.2021.771839https://doaj.org/article/153e29c373eb4cc1b7b86dbb9ba1318c2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.771839/fullhttps://doaj.org/toc/1663-9812Purpose: Triple-negative breast cancer (TNBC) is the most dangerous subtype of breast cancer with high rates of metastasis and recurrence. The efficacy of capecitabine in chemotherapy for TNBC is still controversial. This study evaluated the efficacy and safety of capecitabine combining with standard, adjuvant or neoadjuvant chemotherapy for TNBC.Methods: We systematically searched clinical studies through PubMed, Cochrane library, Embase, Wanfang Database, China Academic Journals (CNKI), and American Society of Clinical Oncology’s (ASCO) annual conference report. Studies were assessed for design and quality by the Cochrane risk of bias tool. A meta-analysis was performed using Review Manager to quantify the effect of capecitabine combined with standard, adjuvant or neoadjuvant chemotherapy on the disease-free survival (DFS) rate and overall survival (OS) rate of TNBC patients. Furthermore, safety analysis was performed to evaluate the adverse events.Results: Twelve randomized controlled clinical trials involving totally 4854 TNBC patients were included, of which 2,214 patients received chemotherapy as control group, and 2,278 patients received capecitabine combining with chemotherapy. The results indicated that capecitabine could significantly improve the DFS [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.71–0.90, P = 0.0003] and OS (HR 0.83, 95% CI 0.74–0.93, P = 0.001). In subgroup analysis, the combination of capecitabine and cyclophosphamide exhibited a significant benefit in all outcomes (DFS HR 0.75, 95% CI 0.63–0.90, P = 0.002; OS HR 0.65, 95% CI 0.52–0.80, p < 0.0001). Additionally, defferent dose of capecitabine subgroup showed same significant effect on the results. Safety analysis showed that the addition of capecitabine was associated with a much higher risk of hand-foot syndrome, diarrhea and mucositis or stomatitis.Conclusion: The results showed that adjuvant capecitabine could bring significant benefits on DFS and OS to unselected TNBC patients, the combination of capecitabine and cyclophosphamide could improve the survival rate of patients, although the addition of capecitabine could bring significant side effects such as hand foot syndrome (HFS) and diarrhea.Zilin ZhangKai MaJing LiYeneng GuanChaobo YangAqin YanHongda ZhuFrontiers Media S.A.articlechemotherapytriple-negative breast cancercapecitabinemeta-analysissafetyTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
chemotherapy triple-negative breast cancer capecitabine meta-analysis safety Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
chemotherapy triple-negative breast cancer capecitabine meta-analysis safety Therapeutics. Pharmacology RM1-950 Zilin Zhang Kai Ma Jing Li Yeneng Guan Chaobo Yang Aqin Yan Hongda Zhu The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis |
| description |
Purpose: Triple-negative breast cancer (TNBC) is the most dangerous subtype of breast cancer with high rates of metastasis and recurrence. The efficacy of capecitabine in chemotherapy for TNBC is still controversial. This study evaluated the efficacy and safety of capecitabine combining with standard, adjuvant or neoadjuvant chemotherapy for TNBC.Methods: We systematically searched clinical studies through PubMed, Cochrane library, Embase, Wanfang Database, China Academic Journals (CNKI), and American Society of Clinical Oncology’s (ASCO) annual conference report. Studies were assessed for design and quality by the Cochrane risk of bias tool. A meta-analysis was performed using Review Manager to quantify the effect of capecitabine combined with standard, adjuvant or neoadjuvant chemotherapy on the disease-free survival (DFS) rate and overall survival (OS) rate of TNBC patients. Furthermore, safety analysis was performed to evaluate the adverse events.Results: Twelve randomized controlled clinical trials involving totally 4854 TNBC patients were included, of which 2,214 patients received chemotherapy as control group, and 2,278 patients received capecitabine combining with chemotherapy. The results indicated that capecitabine could significantly improve the DFS [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.71–0.90, P = 0.0003] and OS (HR 0.83, 95% CI 0.74–0.93, P = 0.001). In subgroup analysis, the combination of capecitabine and cyclophosphamide exhibited a significant benefit in all outcomes (DFS HR 0.75, 95% CI 0.63–0.90, P = 0.002; OS HR 0.65, 95% CI 0.52–0.80, p < 0.0001). Additionally, defferent dose of capecitabine subgroup showed same significant effect on the results. Safety analysis showed that the addition of capecitabine was associated with a much higher risk of hand-foot syndrome, diarrhea and mucositis or stomatitis.Conclusion: The results showed that adjuvant capecitabine could bring significant benefits on DFS and OS to unselected TNBC patients, the combination of capecitabine and cyclophosphamide could improve the survival rate of patients, although the addition of capecitabine could bring significant side effects such as hand foot syndrome (HFS) and diarrhea. |
| format |
article |
| author |
Zilin Zhang Kai Ma Jing Li Yeneng Guan Chaobo Yang Aqin Yan Hongda Zhu |
| author_facet |
Zilin Zhang Kai Ma Jing Li Yeneng Guan Chaobo Yang Aqin Yan Hongda Zhu |
| author_sort |
Zilin Zhang |
| title |
The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis |
| title_short |
The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis |
| title_full |
The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis |
| title_fullStr |
The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis |
| title_full_unstemmed |
The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis |
| title_sort |
clinical value of chemotherapy combined with capecitabine in triple-negative breast cancer—a meta-analysis |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/153e29c373eb4cc1b7b86dbb9ba1318c |
| work_keys_str_mv |
AT zilinzhang theclinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT kaima theclinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT jingli theclinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT yenengguan theclinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT chaoboyang theclinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT aqinyan theclinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT hongdazhu theclinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT zilinzhang clinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT kaima clinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT jingli clinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT yenengguan clinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT chaoboyang clinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT aqinyan clinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis AT hongdazhu clinicalvalueofchemotherapycombinedwithcapecitabineintriplenegativebreastcancerametaanalysis |
| _version_ |
1718428790047113216 |